Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (321-330 of 353) with videos related to

Pageof 36
Sort By:
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Open Heart|October 17, 2022
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseSteven E Nissen, Kathy Wolski, Leslie Cho, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
The New England Journal of Medicine|November 17, 2009
Intravenous platelet blockade with cangrelor during PCIDeepak L Bhatt, A Michael Lincoff, C Michael Gibson, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
Pageof 36

Showing results (321-330 of 353) with videos related to

Sort By:
Pageof 36
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Open Heart|October 17, 2022
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseSteven E Nissen, Kathy Wolski, Leslie Cho, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
The New England Journal of Medicine|November 17, 2009
Intravenous platelet blockade with cangrelor during PCIDeepak L Bhatt, A Michael Lincoff, C Michael Gibson, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
Pageof 36